Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter growth engine: the real-world data business tucked inside its lab-services empire, far from the instruments most investors picture when they hear the name.
Bull Case: A Growth Machine Built On Deals
Thermo Fisher has leaned on acquisitions to expand for years, buying smaller companies and then plugging them into its own sales and distribution network. The pattern shows up in the numbers. In 2025, the company posted revenue of $44.6 billion, up 4%, and EPS of $17.74, up 7%, with the life sciences solutions segment growing revenue 8% to $10.4 billion on stronger bioproduction demand.
Thermo Fisher has kept the deal machine running, agreeing to buy Clario Holdings, which handles endpoint data for clinical trials, in an $8.8 billion deal, on top of last year’s $4 billion purchase of Solventum’s filtration and purification unit. The new vitiligo registry fits that same playbook of adding data and evidence services around its core business. It enrolls adolescents and adults aged 12 and older with dermatologist-confirmed nonsegmental vitiligo across the US, collecting both clinician and patient-reported outcomes to fill gaps around treatment durability and sequencing for therapies including JAK inhibitors. That kind of longitudinal evidence is exactly what drugmakers pay for once a therapy reaches the market, and it extends CorEvitas’ existing autoimmune and dermatology registry portfolio into a new disease area.
Bear Case: A Premium Price For Modest Growth
The company’s own guidance, excluding Clario, calls for 2026 revenue of $46.3 billion to $47.2 billion, roughly 5% growth at the midpoint, a pace that looks unremarkable next to the size of the checks being written for acquisitions. Shares are down more than 15% this year even as Thermo Fisher keeps adding debt-funded deals to the balance sheet, and a single disease registry covering nonsegmental vitiligo is a small addition next to a company generating tens of billions in annual revenue. The dividend yield remains thin at around 0.36%, so income investors are not being paid much to wait out the acquisition strategy, and every new deal raises the question of whether integration keeps pace with the dealmaking itself.
What The Market Is Pricing In
Hedge fund ownership rose to 115 funds last quarter from 113 the quarter before, a modest tick toward accumulation. Short interest sits at just 1.43% of the float, showing little organized bearish positioning. Shares trade at a forward price-to-earnings ratio of 23.87, a premium that assumes the acquisition-fueled growth story keeps working. Rising fund ownership paired with light short interest suggests the market is not particularly worried about the deal-heavy approach right now.
Where This Leaves Investors
The vitiligo registry itself will not move Thermo Fisher’s revenue in any meaningful way, but it shows how the company keeps stacking recurring data and evidence services on top of its core instruments business. The bull case rests on that acquisition engine continuing to convert into real revenue and earnings growth, as it did in 2025.
While we acknowledge the risk and potential of TMO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMO and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center